A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The primary objective of the open-label extension was the long-term assessment of safety and tolerability of ER OROS paliperidone 3 to 15 mg/day in subjects diagnosed with schizophrenia. In addition, the long-term efficacy and effect of ER OROS paliperidone on overall functioning and personal and social functioning, as well as quality of life, health economics, and subjective sleep measures, was explored. This open-label extension study followed a recurrence prevention study (R076477-SCH-301) that had both an open-label run-in/stabilization phase and a double-blind, placebo-controlled phase.
Open-label study drug (ER OROS paliperidone 3 mg to 15 mg/day) was administered for 52 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who had experienced a recurrence event during the double blind phase of Study R076477-SCH-301
Remained recurrence free until the end of the double-blind phase, or were in the run-in or stabilization phases when the study was terminated
Who signed the informed consent for the open-label extension
And who the investigator agreed that open-label treatment was in the best interest of the subject were eligible to participate in the open-label extension
You may not be if
Were pregnant or had received an injection of a depot antipsychotic since entry into the preceding double-blind phase